How has been the historical performance of Concord Biotech?

Answer:The historical performance of Concord Biotech shows a consistent growth trend in net sales and profits over the years.

Breakdown:
Concord Biotech's net sales have increased significantly from INR 712.93 crore in March 2022 to INR 1,200.09 crore in March 2025. This upward trajectory is mirrored in total operating income, which rose from INR 712.93 crore in March 2022 to INR 1,200.09 crore in March 2025. The company's operating profit (PBDIT) also reflects this growth, climbing from INR 296.69 crore in March 2022 to INR 550.78 crore in March 2025. Profit before tax has similarly improved, reaching INR 495.87 crore in March 2025, up from INR 241.16 crore in March 2022. Consequently, profit after tax has risen from INR 178.57 crore in March 2022 to INR 372.96 crore in March 2025. The earnings per share (EPS) have also shown a positive trend, increasing from INR 16.72 in March 2022 to INR 35.53 in March 2025. On the balance sheet, total assets grew from INR 1,312.79 crore in March 2022 to INR 2,034.25 crore in March 2025, while total liabilities increased from INR 1,312.79 crore to INR 2,034.25 crore in the same period. The cash flow from operating activities has remained relatively stable, with a slight decrease from INR 265 crore in March 2024 to INR 244 crore in March 2025, while the net cash outflow in March 2025 was INR 14 crore, compared to a net inflow of INR 11 crore in March 2024. Overall, Concord Biotech has demonstrated strong financial performance with significant growth in sales, profits, and assets over the past few years.